Current Trials
ACTIVE CLINICAL STUDIES AT THE CRCNJ
To find out if you’re eligible, contact us at 973 850 4622 or click on the link to the trial of interest, complete the online form, and we will contact you.
Actively Enrolling
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating The Safety And Efficacy Of Two Doses Of Simufilam In Subjects With Mild-To Moderate Alzheimer's Disease
SPONSOR: Cassava Sciences, Inc
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg tablets of simufilam, twice daily, for 76 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.
clinicaltrials.gov.
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
SPONSOR: Eli Lilly
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease.
clinicaltrials.gov.
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
SPONSOR: Eli Lilly
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
clinicaltrials.gov.
Coming Soon to The CRCNJ
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)
SPONSOR: Hoffmann-La Roche
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD. The planned number of participants for this study is approximately 1200 participants randomized in a 1:1 ratio to receive either gantenerumab or placebo (600 participants randomized to gantenerumab and 600 participants randomized to placebo).
clinicaltrials.gov.
Active But Closed to Enrollment
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
SPONSOR: Roche
This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part. clinicaltrials.gov.
CLOSED TO ENROLLMENT
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance with Donanemab Compared with Aducanumab-avwa in Participants with Early Symptomatic Alzheimer’s Disease
SPONSOR: Eli Lilly
The TRAILBLAZER-ALZ 4 Study will compare how safe and effective two drugs are at removing amyloid plaque in people with early stages of Alzheimer’s disease – an investigational drug and a drug already FDA-approved to treat this condition. Both the investigational drug and the FDA-approved drug are given through a tiny tube into your vein (called an “infusion”). All participants will receive either the investigational drug or the FDA-approved drug.
trailblazer4study.com.
CLOSED TO ENROLLMENT
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
SPONSOR: Eli Lilly
The reason for this study is to see how safe and effective the study drug Donanemab is in participants with early Alzheimer's disease. clinicaltrials.gov.
For additional information, click here.
CLOSED TO ENROLLMENT
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)
SPONSOR: Roche
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose. clinicaltrials.gov.
CLOSED TO ENROLLMENT
Click here to make an appointment or call 973-850-4622 to learn more about how The CRCNJ can help.
